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Diethylstilbestrol (DES) is a synthetic estrogen that was used
widely from about 1940 through the 1960s to prevent late complic-
ations of pregnancy. Although estimates vary, two million women
in the US (Noller and Fish, 1974), and perhaps four million
women worldwide (Newbold, 1993) have been exposed to DES
during pregnancy. In 1953, the results of a clinical trial conducted
at the University of Chicago failed to demonstrate that DES was
beneficial for preventing pregnancy complications (Dieckmann et
al, 1953). Nevertheless, DES remained in use for this indication
until the early 1970s, when adverse effects, including clear cell
adenocarcinoma of the vagina, were noted in prenatally exposed
daughters (Herbst and Scully, 1971). 
Several studies have examined breast cancer risk among women
who received DES during pregnancy. Most found an increase of
risk (Bibbo et al, 1978; Beral and Colwell, 1980; Vessey et al,
1983; Greenberg et al, 1984; Hadjimichael et al, 1984; Colton 
et al, 1993) or mortality (Calle et al, 1996), although the associa-
tion was not always statistically significant (Bibbo et al, 1978; Beral
and Colwell, 1980; Vessey et al, 1983; Hadjimichael et al, 1984).
A few earlier studies also suggested elevated risks of endometrial
(Hoover et al, 1976; Autunes et al, 1979) and ovarian cancer
(Hoover et al, 1977; Bibbo et al, 1978; Hadjimichael et al, 1984)
among women who took DES. A current concern is whether the
use of hormone replacement therapy (HRT) may further increase
the risk of breast cancer in DES-exposed women. 
METHODS 
The purpose of this study was to evaluate long-term cancer risk,
particularly breast cancer risk, among women who were exposed
to DES during pregnancy. In this report, we present further follow-
up and a combined analysis of cancer risk in two cohorts of DES-
exposed women, the Mothers Study cohort, and the Dieckmann
Study cohort. The Mothers Study comprised women ascertained in
the early 1980s through a review of medical records at the Mayo
Clinic in Rochester, MN, Mary Hitchcock Memorial Hospital
(MHMH) in Hanover, NH, a high-risk pregnancy clinic at the
Boston Lying-In Hospital (BLI), in Boston, MA, and a private
obstetrics practice in Portland, ME (Greenberg et al, 1984; Colton
et al, 1993). At MHMH, the private obstetrics practice in Portland
and the Mayo Clinic cohort members were identified through 
a retrospective review of obstetrics records for the period
1940–1960. DES-exposed women were those whose records indic-
ated that DES (or, rarely, another nonsteroidal oestrogen) had been
prescribed during at least one pregnancy resulting in a live birth.
The date of the first DES-exposed live birth was the study 
entry date. Records from the same four sources were used to
assemble a comparison sample of unexposed women who had
delivered at least one live birth during the same time period
(1940–1960), and whose charts did not indicate exogenous
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were matched within ± 2 years to the DES-exposed women’s birth
dates, and were assigned the same date of study entry as the
exposed woman to whom they were matched. Comparable ascer-
tainment procedures were followed at BLI, except that exposed
women were identified through a high-risk pregnancy clinic, and
unexposed women were sampled from the card file of all patients.
Previous follow-up of women in the DES Mothers Study cohort
occurred in 1981, 1986, and 1989 (Greenberg et al, 1984; Colton
et al, 1993). 
The Dieckmann Study cohort consists of women participating in
a clinical trial that examined the effects of DES on pregnancy
outcomes. The Dieckmann trial, conducted in the early 1950s at
the University of Chicago, enrolled women who were 6–20 weeks
pregnant. Women who entered the prenatal clinic were alternately
assigned to receive DES or placebo; the date of pregnancy
outcome was the study entry date. Participants in the Dieckmann
Study were evaluated in 1976 for cancer outcomes (Bibbo et al,
1978). In 1992, members of the cohort were re-contacted in
conjunction with renewed follow-up of the Mothers Study 
cohort. 
Follow-up 
During 1992, we undertook intensive tracing efforts to locate
women who had been previously followed. A total of 625 women
(262 exposed, 363 unexposed), comprising 8% of the initial
cohorts (7% of exposed, 9% of unexposed), could not be located
(Table 1). In 1994, we sent follow-up questionnaires to women
who were presumed alive, who had not previously refused further
contact, and for whom addresses were available. If a woman did
not respond after two mailings, we attempted a telephone inter-
view. Through these procedures, we obtained completed question-
naires from 4836 women approached for follow-up, including
2434 (88%) exposed and 2402 (89%) unexposed women. An addi-
tional 638 women (327 exposed, 311 unexposed) either refused to
participate or did not respond to our efforts to contact them. We
searched the National Death Index for women who could not be
located, and obtained death certificates for women known to have
died. Death certificates were coded by a nosologist. A total of
1659 deaths (856 exposed, 803 unexposed) were ascertained 
since the initiation of follow-up. Complete follow-up (either a
completed 1994 questionnaire or a death certificate) was obtained
for 84% (6495/7758) of women (85% exposed, 83% unexposed)
who had been enrolled in the initial cohorts. Follow-up was more
complete for the Mothers Study cohort (88%) than the Dieckmann
Study cohort (69%), and was comparable for exposed and
unexposed women in each cohort. 
Cancers recorded prior to the 1994 follow-up had been con-
firmed by the medical record or death certificate. A total of 621
new invasive cancers were reported on the 1994 questionnaire;
medical records were obtained for 551 (89%), of which 510 (93%)
confirmed the reported diagnosis. The reported cancers included
251 invasive breast cancers; medical records were obtained for
231 (92%), of which 225 (97%) confirmed the reported diagnosis. 
Statistical analyses 
The analyses presented here are based on the diagnosis of invasive
cancer confirmed by a review of the medical record, or ascertained
through underlying cause of death listed on the death certificate.
We compared cancer risk in the DES-exposed women to that in the
unexposed cohort and in the general population. Person-years
were calculated from the date of study entry until the earliest of 
the following events: date of cancer diagnosis, date of death, or the
date of the last known follow-up. If a woman had more than 
one cancer diagnosis, person-years were accrued until the date of
the diagnosis of interest; in the analyses of all cancers, person-
years were accrued until the earliest cancer diagnosis. A total of
3844 exposed women (contributing 143 567 person years) and
3716 unexposed women (contributing 139 735 person years) were
available for the combined cancer analyses. For analyses of
endometrial and ovarian cancer, women who had hysterectomies
exited the analyses at the date of surgery. 
Analyses were conducted separately for the Mothers Study and
Dieckmann Study cohorts, and in the two cohorts combined.
Poisson regression analyses were used to estimate the risk of
cancer in DES-exposed vs unexposed women, controlling for age,
calendar year, and cohort (in the combined analyses) (Breslow and
Day, 1987). For breast cancer, we evaluated potential confounding
by years of education, family history of breast cancer, age at
menarche, oral contraceptive use, number of pregnancy losses, age
at first full-term birth, parity, menopausal status and HRT use.
Potential confounders in analyses of ovarian cancer risk were oral
contraceptive use, parity, and use of HRT; potential confounders in
analyses of endometrial cancer risk were body mass index, oral
contraceptive use, parity, and HRT. In all analyses, menopause and
HRT were treated as time-dependent variables. Other variables
were evaluated using the categories shown in Table 2. In general,
covariates were based on the most recent information, although
age at menarche was taken from the earliest record available. 
We used stratified analyses to evaluate the effect of DES on
breast cancer risk according to age at study entry, attained age, and
time since exposure. The influence of DES was also evaluated
according to family history of breast cancer, oral contraceptive
use, number of pregnancy losses, age at first full-term birth, parity,
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Table 1 Status of cohorts 
Mothers Study Dieckmann Study 
Exposed Unexposed Exposed Unexposed Total 
Initial members 3053 3075 826 804 7758 
Ever followed 2885 2816 693 668 7062 
Deceased 698 678 158 125 1659 
Approached in 1994 2243 2215 518 498 5474 
Questionnaire returned 2019 1978 415 424 4836 
Questionnaire not returned 224 237 103 74 638 
Whereabouts unknown 112 182 150 181 625 128 L Titus-Ernstoff et al
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Table 2 Number (and percent) of DES-exposed and- unexposed women according to select characteristics, by cohort 
Mothers Study Dieckmann Study 
Factor Exposed Unexposed Exposed Unexposed 
Age at study entry (years) 
< 25 882 (29.1) 868 (28.8) 218 (26.4) 219 (27.2) 
25–29 1059 (35.0) 1051 (34.9) 302 (36.6) 293 (36.4) 
30–34 643 (21.2) 669 (22.2) 189 (22.9) 196 (24.4)
≥ 35 445 (14.7) 424 (14.1) 117 (14.2) 96 (11.9) 
Body mass indexa (kg m–2) 
< 21 319 (13.8) 297 (13.4) 46 (9.6) 60 (12.1) 
21–23 900 (38.9) 813 (36.6) 140 (29.3) 122 (24.6)
24–27 741 (32.1) 776 (34.9) 151 (31.6) 181 (36.5)
≥ 28 351 (15.2) 336 (15.1) 141 (29.5) 133 (26.8)
missing 718 790 348 308 
Education (years)b
0–8 164 (6.7) 188 (8.0) ––  
9–12 1205 (49.0) 1139 (48.5) ––  
13–16 899 (36.5) 838 (35.7) ––  
≥ 17 193 (7.8) 182 (7.8) ––  
missing 568 665 826 804 
Family history of breast cancer 
no 2606 (86.0) 2660 (88.3) 729 (88.3) 703 (87.4) 
yes 423 (14.0) 352 (11.7) 97 (11.7) 101 (12.6) 
Age at menarche 
< 12 404 (14.6) 322 (12.3) 120 (15.0) 126 (16.4) 
12, 13 1524 (54.9) 1492 (56.9) 446 (55.6) 413 (53.8)
≥ 14 848 (30.6) 808 (30.8) 236 (29.4) 228 (29.7)
missing 253 390 24 37 
Oral contraceptive use 
no 1923 (78.8) 1872 (80.3) 578 (79.3) 564 (82.1) 
yes 518 (21.2) 460 (19.7) 151 (20.7) 123 (17.9) 
missing 588 680 97 117 
Pregnancy losses 
0 1038 (39.2) 1558 (63.3) 511 (66.2) 482 (66.0) 
1 764 (28.9) 616 (25.0) 165 (21.4) 158 (21.6) 
≥ 2 846 (32.0) 288 (11.7) 96 (12.4) 90 (12.3) 
missing 381 550 54 74 
Age at first full-term birth 
< 20 367 (12.2) 441 (14.8) 69 (8.5) 75 (9.5) 
20–24 1329 (44.2) 1501 (50.2) 345 (42.3) 328 (41.6) 
25–29 895 (29.8) 772 (25.8) 289 (35.4) 280 (35.5)
≥ 30 414 (13.8) 275 (9.2) 113 (13.9) 105 (13.3) 
missing 24 23 10 16 
Parity 
1,2 589 (24.2) 591 (25.5) 257 (32.5) 241 (32.0) 
3,4 1147 (47.2) 1113 (48.0) 392 (49.6) 363 (48.2) 
≥ 5 694 (28.6) 613 (26.5) 141 (17.9) 149 (19.8) 
missing 599 695 36 51 
Age at menopause 
< 39 321 (13.8) 265 (11.8) 44 (7.8) 51 (9.1) 
40–44 552 (23.8) 474 (21.2) 77 (13.7) 83 (14.9) 
45–49 532 (22.9) 533 (23.8) 160 (28.5) 158 (28.3)
50–54 756 (32.5) 799 (35.7) 218 (38.8) 212 (37.9)
≥ 55 163 (7.0) 169 (7.5) 63 (11.2) 55 (9.8) 
missing 705 772 264 245 
Hormone replacement therapy 
no 1644 (65.4) 1689 (70.0) 536 (68.9) 453 (62.5) 
yes 870 (34.6) 725 (30.0) 242 (31.1) 272 (37.5) 
missing 515 598 48 79 
Hysterectomy 
no 1885 (62.2) 2040 (67.7) 548 (66.3) 517 (64.3) 
yes 1144 (37.8) 972 (32.3) 278 (33.7) 287 (35.7) 
Ever smoked 
no 1187 (45.9) 1158 (47.0) 512 (62.2) 507 (63.5) 
yes 1401 (54.1) 1308 (53.0) 311 (37.8) 292 (36.6) 
missing 441 546 3 5 
aBMI based on weight at age 50 for DES Mothers Study cohort, and on current weight at most recent questionnaire
response for the Dieckmann cohort; bnot available for the Dieckmann cohort. menopausal status, and HRT use. Additional analyses assessed the
influence of DES on ovarian and endometrial cancer risk
according to use of HRT. Potential interactions between DES and
other risk factors were assessed using the likelihood ratio test
(Breslow and Day, 1987). 
Age-standardized cancer rates for DES-exposed and unexposed
women were calculated using the 1970 US population as a stand-
ard. For external comparisons, we used cancer incidence rates 
for women from the Connecticut Tumor Registry (Heston et al,
1986) for the years prior to 1970, and from the Surveillance,
Epidemiology, and End Results (SEER) program (Ries et al, 1999)
for the years 1970–1994 (for white women). Expected numbers of
cancers were generated by applying age- and calendar year-
specific incidence rates to the appropriate person-years at risk. We
computed standardized incidence ratios (SIRs) and their 95%
confidence intervals assuming a Poisson distribution for the
observed numbers of cancers (Breslow and Day, 1987). 
For exposed women, we calculated the proportion of breast
cancer due to DES exposure (i.e., the attributable risk) as RR–1/
RR (Kelsey et al, 1986). 
RESULTS 
Compared to the Dieckmann Study, Mothers Study participants
had higher parity, younger age at first full-term birth, younger 
age at menopause, and higher frequency of cigarette smoking
(Table 2). Mothers Study participants also appeared to have lower
body mass index, but this likely reflected the earlier age at which
weight was ascertained in this cohort (average 50 years), com-
pared to the Dieckmann Study cohort (average 70 years): They
also reported more pregnancy losses, the primary clinical indica-
tion for DES use. 
Within each of the cohorts, exposed and unexposed women
were generally comparable when considered according to educa-
tion (available only in the Mothers Study), age at menarche, parity,
and smoking histories (Table 2). In the Mothers Study cohort,
exposed women were older than unexposed women at first full-
term birth, reported a higher number of pregnancy losses, and were
more likely to have a family history of breast cancer. 
In comparison to unexposed women, DES-exposed women in
both cohorts had a slightly elevated cancer risk, although the effect
was small in the Mothers Study, and consistent with chance in both
cohorts (Table 3). In the combined cohort, the RR of cancer was
1.10 (95% CI = 0.99–1.23). The only significantly elevated risk
was for breast cancer, which accounted for most of the excess
observed in all cancer. Although risks of lung cancer and non-
Hodgkins lymphomas were somewhat elevated in both cohorts,
these were not statistically significant. The age-standardized rates
for all cancer per 100 000 were 289.2 for exposed women, and
249.6 for unexposed women. Relative to the general US popula-
tion rates, cancer rates for the combined cohort were reduced for
DES-exposed women (SIR = 0.88, 95% CI = 0.82–0.95), and for
unexposed women (SIR = 0.80, 95% CI = 0.74–0.87). The SIRs
were similar when based on self-reported cancers. 
DES exposure was associated with an increased breast cancer
risk both in the Mothers Study cohort (RR = 1.29, 95% CI =
1.06–1.57) and, though non-significantly, the Dieckmann Study
(RR = 1.23, 95% CI = 0.85–1.78) (Table 3). When unconfirmed
cases were included in the analyses, the results were similar for the
Mothers Study (RR = 1.26, 95% CI = 1.04–1.53) and Dieckmann
Study cohorts (RR = 1.26, 95% CI = 0.88–1.82). For the combined
cohort, the relative risk (RR) of breast cancer was 1.27 (95% CI =
1.07–1.52); the association was essentially unchanged (RR = 1.25,
95% CI = 1.05–1.50) after adjustment for potential confounders.
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Table 3 Number of confirmed cancersa, relative risksb (RR) and 95% confidence intervals (CI) for cancer sites, and for all cancers, by cohort 
Mothers Study Dieckmann Study Combined cohort 
Cancer site Exp. Unexp. RR (95% CI) Exp. Unexp. RR (95% CI) RR (95% CI) 
All cancers 561 509 1.07 (0.95–1.21) 132 100 1.28 (0.98–1.66) 1.10 (0.99–1.23) 
Oesophagus 2 6 0.32 (0.07–1.06) 0 0 ––  
Stomach 9 5 1.74 (0.58–5.20) 2 0 – 2.13 (0.74–6.14) 
Colorectal 71 71 1.06 (0.77–1.47) 13 7 1.80 (0.72–4.51) 1.13 (0.83–1.53) 
Liver 6 5 1.16 (0.35–3.79) 1 0 – 1.35 (0.43–4.25) 
Biliary 5 3 1.67 (0.40–6.99) 0 0 ––  
Pancreas 18 16 1.09 (0.55–2.13) 1 1 0.97 (0.06–15.55) 1.08 (0.56–2.08) 
Lung 72 55 1.27 (0.89–1.80) 16 10 1.59 (0.72–3.50) 1.31 (0.95–1.81) 
Lymph/haematc 46 39 1.14 (0.74–1.75) 5 4 1.22 (0.33–4.55) 1.14 (0.76–1.72) 
Non-Hodgkins 31 21 1.43 (0.82–2.48) 3 2 1.42 (0.24–8.49) 1.43 (0.84–2.42) 
Hodgkins 1 4 0.24 (0.03–2.16) 0 0 – 0.24 (0.03–2.16) 
Melanoma 15 16 0.90 (0.45–1.83) 3 2 1.56 (0.26–9.38) 0.97 (0.50–1.86) 
Connective tissue 7 3 2.30 (0.59–8.89) 0 0 ––  
Breast 227 172 1.29 (1.06–1.57) 63 49 1.23 (0.85–1.78) 1.27 (1.07–1.52) 
Cervical 11 21 0.51 (0.25–1.06) 5 1 4.71 (0.55–40.45) 0.71 (0.37–1.35) 
Endometrial 34 35 1.01 (0.63–1.62) 8 11 0.66 (0.27–1.65) 0.92 (0.60–1.39) 
Ovarian 22 32 0.67 (0.39–1.15) 6 6 0.94 (0.30–2.93) 0.72 (0.44–1.17) 
Urinary tract d 8 9 0.85 (0.33–2.21) 4 1 3.65 (0.41–32.73) 1.15 (0.50–2.66) 
Bladder 10 7 1.37 (0.52–3.61) 1 1 0.95 (0.06–15.22) 1.32 (0.53–3.29) 
Brain 6 10 0.58 (0.21–1.59) 1 2 0.49 (0.04–5.44) 0.56 (0.22–1.42) 
Thyroid 7 8 0.85 (0.31–2.33) 1 3 0.33 (0.03–3.15) 0.71 (0.28–1.75) 
Unspecified 14 22 0.61 (0.31–1.20) 4 4 0.95 (0.24–3.81) 0.67 (0.37–1.22) 
Person years 115 853 112 840  27 714 26 886 
aIncludes sites with at least eight confirmed cases; badjusted for age, calendar year, and the interaction between age and calendar year; clymphatic and
haematopoietic malignancies, ICD-9 codes 200–208; dother than urinary bladder The combined cohort results were also similar when study exit
dates for nonrespondents and women lost to follow-up were
extended to the end of the follow-up period. The graph of cumula-
tive breast cancer incidence for the combined cohort, by exposure
status, indicates that risk began to diverge within 10 years of expo-
sure (Figure 1). 
The age-standardized breast cancer rates per 100 000 were
106.9 for exposed women, and 83.9 for unexposed women in the
combined cohort. Relative to the general US population, the
incidence rate was slightly elevated among DES-exposed women 
(SIR = 1.10, 95% CI = 0.98–1.23), and slightly but significantly
reduced among unexposed women (SIR = 0.86, 95% CI = 0.75–
0.98). The SIRs were similar when based on self-reported breast
cancers. 
There was little indication that the association between DES and
breast cancer risk differed according to age at study entry or
attained age (Table 4). The increased risk was evident for four
decades following DES exposure, but was not apparent 40 or 
more years after exposure. The association between DES and
breast cancer risk was not significantly modified by other factors
(Table 5) including family history of breast cancer, or oral contra-
ceptive or HRT use. In an analysis confined to DES-exposed
women, the RR for breast cancer associated with DES exposure
during a first pregnancy compared to a subsequent pregnancy, was
1.15 (95% CI = 0.90–1.47). 
In the combined cohort, DES exposure was not associated with
increased risk of endometrial (RR = 0.92, 95% CI = 0.60–1.39) or
ovarian cancer (RR = 0.72, 95% CI = 0.44–1.17) (Table 3); the
results were similar when adjusted for potential confounders. The
influence of DES on risk of ovarian cancer was not greater for
women who used HRT (RR = 0.34, 95% CI = 0.09–1.28). The
association between DES and risk of endometrial cancer was
somewhat, but not significantly elevated for women who used
HRT (RR = 1.19, 95% CI = 0.56–2.55). There was no evidence of
a statistical interaction between DES and use of HRT in relation to
either ovarian or endometrial cancer. 
DISCUSSION 
Our results indicate that women who took DES during pregnancy
have a modest increased of breast cancer but they showed no
significant increase in risk of other cancers, including ovary or
endometrium cancers. These results are based on the largest study
to date of women with documented exposure to DES during
pregnancy. Our analyses of the combined cohort were based on
over 500 breast cancer cases, including an additional 225 new
diagnoses ascertained since the previous follow-up. A unique
feature of this study is the ability to compare the results of two
cohorts, one identified through prenatal record review, and the
other based on a clinical trial of the effectiveness of DES. This is
130 L Titus-Ernstoff et al
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Table 4 Relative risksa (RR) and 95% confidence intervals (CI) for the relation between DES exposure and breast
cancer risk for the combined cohort, according to age at study entry, attained age, and time since DES exposure 
DES-exposed Unexposed 
Factor n person years n person years RR (95% CI) 
Age at study entry 
< 25 63 47 236 52 46 407 1.19 (0.82–1.71) 
25–29 102 50 602 85 49 986 1.20 (0.90–1.60) 
30–34 83 31 087 53 30 464 1.55 (1.09–2.18) 
≥ 35 42 17 338 31 15 696 1.21 (0.76–1.92) 
Attained ageb
< 40 11 43 927 10 42 946 1.08 (0.46–2.55) 
40–49 55 35 799 36 34 863 1.49 (0.98–2.27) 
50–59 88 32 800 72 32 170 1.20 (0.88–1.63) 
60–69 96 24 544 71 23 912 1.32 (0.97–1.79) 
≥ 70 40 9092 32 8663 1.19 (0.75–1.89) 
Time since exposure (years) 
0–9 10 37 198 7 36 143 1.39 (0.53–3.64) 
10–19 53 36 119 36 35 184 1.44 (0.94–2.19) 
20–29 83 33 964 67 33 050 1.21 (0.87–1.66) 
30–39 101 27 975 65 27 840 1.52 (1.11–2.07) 
≥ 40 43 11 008 46 10 836 0.92 (0.61–1.39) 
aAdjusted for age, calendar year, the interaction between age and calendar year, and cohort; bAge at diagnosis for
cases; age at exit for non-cases also the first study with both confirmed DES exposure and reason-
able statistical power to assess whether DES is associated with
hormonally mediated cancers other than breast cancer. 
Our finding of a 27% increased breast cancer risk is consistent
with the earlier follow-up of the Mothers Study (Greenberg et al,
1984; Colton et al, 1993), and with studies of Connecticut women
(Hadjimichael et al, 1984) and of fatal breast cancer (Calle et al,
1996). The initial report of the Dieckmann follow-up did not indic-
ate an effect of DES on breast cancer risk, but a re-analysis of the
data showed a non-significant 47% increase in risk (based on 53
cases), and a nearly three-fold and marginally significant increase
in breast cancer mortality (based on 16 cases) (Clark and Portier,
1979). Other studies with inconclusive (Beral and Colwell, 1980)
or null results (Vessey et al, 1983) were also small in size. 
In our data, the breast cancer risk was increased in DES-exposed
women relative both to unexposed women and to US population
rates. The women in our study were parous, perhaps accounting
for the lower rate of breast cancer among unexposed women,
relative to the general population. We also noted reduced rates of
cancer at all sites combined, relative to the general population.
This may reflect the better health of parous women, and protective
lifestyle factors among women who, for the most part, sought
obstetric care at teaching hospitals (Greenberg et al, 1984). 
In this study, the influence of DES on breast cancer risk was
fairly constant in the presence of other hormonal factors, including
oral contraceptives, menopausal status, and HRT. Similar results
were found in the study of fatal breast cancer (Calle et al, 1996).
As in the initial follow-up of the Mothers Study cohort (Greenberg
et al, 1984) and the study of fatal breast cancer (Calle et al, 1996),
we found no evidence that the effect of DES was greater among
women who had previous pregnancy losses or breast cancer in
their families. We also found no evidence, in an analysis confined
to DES-exposed women, that breast cancer risk was greater for
women exposed during their first pregnancy, relative to a subse-
quent pregnancy. 
In practice, women who were prescribed DES were often those
with a history of high-risk pregnancies, raising the possibility that
the relationship between DES and breast cancer risk was
confounded by hormonal factors associated with pregnancy
complications. In this study, we found no evidence of confounding
by a history of pregnancy losses, or known breast cancer risk
factors. The increased risk was also observed in the Dieckmann
Study participants, whose use of DES was unrelated to potential
confounders, including prior pregnancy losses. The association
between DES and breast cancer risk is also unlikely to be an
artifact of increased surveillance of the DES-exposed women.
Previous follow-up of the Mothers Study cohort showed that the
frequency of breast self-examination, breast examination by a
physician, mammography, and stage of diagnosis were similar for
exposed and unexposed women (Greenberg et al, 1984; Colton 
et al, 1993). In addition, previous follow-up of the Mothers
(Colton et al, 1993) and Dieckmann Study cohorts (Bibbo et al,
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Table 5 Relative risksa (RR) and 95% confidence intervals (CI), for the relationship between DES exposure and breast cancer risk
in the combined cohort, according to select breast cancer risk factors 
DES-exposed Unexposed 
Factor n person years n person years RR (95% CI)  Pc
Family history of breast cancer 
no 227 125 544 178 124 333 1.25 (1.03–1.53) 0.85 
yes 63 20 719 43 18 220 1.31 (0.89–1.93) 
Oral contraceptive use 
never 188 102 691 141 101 125 1.31 (1.05–1.62) 0.85 
ever 47 26 968 36 23 790 1.16 (0.75–1.79) 
missing 55 16 604 44 17 638 
Pregnancy losses 
0 126 62 185 118 83 530 1.43 (1.11–1.84) 0.46 
≥ 1 134 73 366 73 44 956 1.13 (0.85–1.50) 
missing 30 10 706 30 14 063 
Age at first full-term birth (years) 
< 20 20 16 347 21 18 155 1.14 (0.61–2.12) 0.69 
20–24 110 64 446 106 68 749 1.15 (0.88–1.50) 
25–29 99 45 423 66 40 593 1.32 (0.97–1.81) 
≥ 30 57 19 058 26 14 176 1.72 (1.07–2.75) 
missing 4 989 2 879 
Parity 
1,2 65 33 142 52 33 054 1.26 (0.87–1.82) 0.43
3,4 127 62 368 82 60 951 1.52 (1.15–2.00) 
≥ 5 48 34 843 43 31 445 1.02 (0.68–1.55) 
missing 50 15 910 44 17 103 
Menopausal statusb
premenopause 29 56 020 20 55 951 1.50 (0.85–2.65) 0.23 
postmenopause 179 67 321 151 64 122 1.14 (0.92–1.41) 
missing 82 22 916 50 22 475 
Hormone replacement therapyb
no 171 105 589 126 105 384 1.37 (1.08–1.72) 0.64 
yes 48 19 632 40 17 533 1.10 (0.72–1.68) 
missing 71 21 036 55 19 630 
aAdjusted for age, calendar year, the interaction between age and calendar year, and cohort; bTreated as a time-dependent variable; 
cP value for the interaction with DES, based on the likelihood ratio test. 132 L Titus-Ernstoff et al
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1978), and the results of a recent study (Calle et al, 1996) have
shown an association between DES and breast cancer mortality. 
A possible limitation of our study was the long interim between
evaluations of the Dieckmann cohort and consequent losses to
follow-up. Ascertainment of vital status was comparable, however,
for exposed and unexposed women in the Dieckmann cohort. We
also found similar results with regard to breast cancer risk when
the follow-up of untraceable and non-responding women was 
extended to the study end-date. 
Although the increased risk associated with DES exposure is
modest, an approximately 30% increased risk translates into a
substantial number of excess cases for a disease as common as
breast cancer. If DES is causally related to breast cancer risk, the
results of our study indicate that it accounts for 21% of the breast
cancer cases among DES-exposed women. A causal role would be
more credible with evidence of a dose–response relationship, but
this could not be evaluated in our study. Details of DES doses were
often missing from the obstetrics records of Mothers Study partic-
ipants, and were administered according to a standard protocol in
the Dieckmann Study participants. However, in the study of
Connecticut women, the increased breast cancer risk was similar
for varying DES dose levels (Hadjimichael et al, 1984). The influ-
ence of DES exposure on breast cancer risk in cohorts with
different average (or median) dose levels is not consistent with a
dose–response relationship. For example, RRs were comparable in
the study of Connecticut women, whose average total dose of DES
was 2.1 g (Hadjimichael et al, 1984), and in the Dieckmann Study
cohort (Clark and Portier, 1979), where the total dose was 11–12 g
(Bibbo et al, 1978). A possible causal role for DES receives some
support from evidence for an association between HRT and breast
cancer risk (Colditz et al, 1995; CGHFBC, 1997; Schairer et al,
2000), generally with recent, long-term use; in contrast, DES
exposure was brief, even for women with multiple exposed preg-
nancies, and the effect persisted for four decades. The dose levels
of DES were relatively high, perhaps increasing the plausibility of
an association with breast cancer risk. For women in the
Dieckmann Study, for example, DES doses were 300-fold greater
than the amount typically used for 1 year of hormone replacement
(0.1 mg per day) (Noller and Fish, 1974). The persisting effect of
DES may be due to the high dose levels administered, the pharma-
cological properties of non-steroidal oestrogens (DES) (which
differ from those of natural conjugated oestrogens), or the suscep-
tibility of breast tissue during pregnancy. 
In this study, DES was not significantly associated with specific
cancer sites other than the breast. In particular, DES was not
related to increased risk of endometrial cancer, despite the known
association between oestrogen replacement therapy and endomet-
rial cancer. The results of some previous studies suggested an asso-
ciation with decreased risk of endometrial cancer (Bibbo et al,
1978; Hadjimichael et al, 1984), whereas others reported increased
risks (Hoover et al, 1976; Autunes et al, 1979). We found no
evidence that DES exposure was associated with increased 
risk of ovarian cancer. Previous studies suggested increased risk of
ovarian (Hoover et al, 1977; Bibbo et al, 1978; Hadjimichael 
et al, 1984), and possibly cervical cancer (Bibbo et al, 1978;
Hadmichael et al, 1984), but case numbers were small, and the
findings were not statistically precise. 
In summary, women who took DES while they were pregnant
experience a 20–30% increased rate of breast cancer for many
years thereafter. This modest increase in risk does not appear to be
greater or lesser depending upon family history of breast cancer. It
also appears not to be exacerbated by use of oral contraceptives or
HRT. DES appeared not to increase the risk of other cancers,
including endometrial or ovarian cancer. 
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